Biotech

All Articles

FDA places Kezar lupus test in hold following 4 client deaths

.The FDA has positioned Kezar Life Sciences' lupus trial on hold after the biotech flagged four fata...

Phase 3 Historian Rock test attacks SMA target, sending out stockpile 200%

.A phase 3 test of Scholar Stone's spine muscle atrophy (SMA) prospect has actually hit its key endp...

CAMP 4 is most up-to-date to eye IPO, while Upstream describe $182M program

.RNA biotech CAMP4 Therapies has marked out think about a $67 thousand IPO, along with inflammation-...

Galecto gets leukemia drug, drops bone cancer cells asset in pivot

.A year after the failing of an idiopathic lung fibrosis applicant delivered Galecto on a seek salva...

Judo tosses down $100M to knock senseless kidney disease

.Taking the mat is Judo Bio, an ambitious biotech equipped with $one hundred million to develop olig...

AstraZeneca pays out CSPC $100M for preclinical heart problem medication

.AstraZeneca has settled CSPC Pharmaceutical Team $one hundred thousand for a preclinical heart atta...

Zephyrm seeks Hong Kong IPO to finance period 3 tissue treatment tests

.Zephyrm Bioscience is gusting toward the Hong Kong stock market, filing (PDF) for an IPO to money p...

Frazier Lifestyle Sciences gathers $630M for small, mid-cap biotechs

.Frazier Lifespan Sciences has sourced an even further $630 thousand for its fund focused on tiny an...

GigaGen gathers up to $135M BARDA money to hammer botulism

.Antibody fanatic GigaGen, a subsidiary of Spanish biopharma Grifols, is actually ramping up its tec...

GPCR firm Septerna files for IPO on stamina of preclinical data

.Septerna is about to find out exactly how a biotech without "any kind of meaningful professional re...